Article Text
Letters
PostScript
Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves’ disease
Statistics from Altmetric.com
Footnotes
-
Competing interests: DEF, CHN and LH have conducted a trial on the use of rituximab in Graves’ disease which received funding support from Roche Denmark A/S. CHN has received lecture fees from Roche Denmark A/S. JK and OC have nothing to declare.
-
Funding: The Agnes and Knut Mørk Foundation, The Danish Thyroid League, The Novo Nordisk Foundation, and Roche Denmark A/S provided grant support. DEF is the recipient of a research fellowship from the Institute of Clinical Research at The University of Southern Denmark. The funding sources have had no influence on the design of the study; on collection, analysis or interpretation of the data; in the writing of the report; nor on the decision to submit the paper for publication.